On April 23, 2026, the Department of Justice announced an order placing FDA-approved marijuana products and marijuana products under a qualifying state-issued medical license in Schedule III of the Controlled Substances Act, a change formalized in the Federal Register rescheduling document. For a compliant medical dispensary, the most expensive line in the entire model fell away. Section 280E of the tax code, which denies ordinary business deductions to sellers of Schedule I and II substances, no longer reaches a medical operation once its product sits in Schedule III. Whitney Economics estimates the industry paid about 2.24 billion dollars in excess federal taxes in 2025 alone under 280E, and more than 15 billion dollars since 2018, with effective rates that can approach 70 percent or more for retailers.
This article is for operators who run both medical and adult-use under one roof, and it makes one point first: rescheduling did not legalize cannabis, and it did nothing for the recreational side of the business. The order reclassified only medical marijuana under a state license and FDA-approved cannabis drugs. Adult-use cannabis stays on Schedule I and stays fully subject to 280E. The federal government just split what most MSOs operate as one vertically integrated business into two distinct tax regimes. If your accounting, your seed-to-sale records, and your tax planning do not yet reflect that split, you are exposed on both sides: overpaying tax you no longer owe, and claiming relief you cannot defend.
The two-regime problem is now an accounting problem
The medical and adult-use distinction is no longer a licensing label. It is the line between two tax treatments running inside the same facility. For a vertically integrated operator cultivating, processing, and selling across both channels, expenses now have to be allocated with a precision that 280E never demanded, because under 280E nothing below the line was deductible at all.
That changes the job of your seed-to-sale system. It moves from a compliance ledger to a tax-substantiation engine. Tag data, which state regulators routinely reconcile against physical inventory during inspections, now also has to support the split of shared costs between Schedule III medical product and Schedule I adult-use product. Cultivation labor, facility rent, utilities, security, packaging: each shared cost needs an allocation key tied back to the medical versus adult-use designation in your tracking records. A plant tagged, grown, and sold through the medical channel carries deductible expenses. The genetically identical plant in the next row, sold adult-use, carries the same costs as non-deductible under 280E. Your cost-accounting method has to defend that line item by item, using the audit trail your tracking system already produces.
Operators who treat this as a quarter-end cleanup will lose money. The defensible move is to configure cost centers and inventory tagging now, so every shared expense carries an allocation key anchored in your seed-to-sale data. That is the difference between a clean Schedule III deduction position and an IRS adjustment that claws back the relief you thought you captured.
The June 22 deadline is real and procedural
The DOJ order opened a 60-day window for state-licensed medical marijuana businesses to file for federal DEA registration. That window closes June 22, 2026. This is not the broader rescheduling fight. It is the mechanical step that lets a medical operator work within the Schedule III structure. Larger operators are already moving, with several multistate operators reporting they have begun the DEA registration process.
For compliance officers, registration is not academic. Schedule III substances carry DEA registration, recordkeeping, and security obligations that Schedule I cannabis operators never had to satisfy at the federal level, because they operated outside federal law rather than inside it. Filing for registration is the act that brings a medical operation inside the regulated federal perimeter. Missing the June 22 window risks leaving a medical operation in a gap where it has neither the protection of registration nor the clarity of being uniformly illegal. Every operator with a medical license should reach a documented, counsel-reviewed answer on registration before that date.
The June 29 hearing decides whether adult-use ever catches up
Alongside the order, the DEA set an expedited administrative hearing to begin June 29, 2026 on the broader rescheduling of all cannabis from Schedule I to Schedule III. The notice governing the hearing set the deadlines for participation and evidence submission through May and June. If the process holds to the announced timeline, a final rule extending Schedule III treatment more broadly could publish later in 2026, though litigation could push that out.
For operators, June 29 decides whether the current split is a temporary distortion or the structure you run inside for years. Recreational-heavy operators in adult-use-only states gained nothing from the order and still carry the full 280E burden. The strategic question for any MSO is not whether rescheduling helped, but what the adult-use exposure looks like if Schedule III treatment never reaches recreational product. A financial model that runs both paths, broad rescheduling by year-end against an indefinite medical-only carve-out, is now table stakes for capital planning, because the two paths produce very different free-cash-flow profiles.
Retroactive relief: plan for it, do not bank on it
The Treasury Department and IRS announced a process for issuing tax guidance following the DOJ final order, including how 280E treatment applies to qualifying medical businesses. That process is the thing to watch on retroactive relief for prior tax years. Operators should preserve the documentation needed to file protective refund claims for open medical tax years, because if guidance opens that door, the firms with clean allocable records collect and the firms with commingled books spend years substantiating. No operator should book retroactive relief as expected revenue or borrow against it. Treat it as contingent upside that rewards good recordkeeping, not a line in the forecast.
What the marketing side still cannot do
Rescheduling changes nothing about advertising and outreach compliance, and enforcement there has only sharpened. The FCC one-to-one consent rule, which took effect January 27, 2025 and amended the definition of prior express written consent in the Federal Register robocall order, exposes cannabis marketers to statutory damages under the TCPA, and plaintiffs' firms are actively targeting cannabis, hemp, and lead-generation senders. Consent must be specific, brand-named, documented, and age-gated. A medical operator that just captured a 280E windfall should not hand it back through a class-action SMS settlement. The consent capture, revocation handling, and audit logging stack deserves the same rigor as the tax allocation work, because the downside is measured in the same dollars.
Priorities for the next 21 days
- Resolve DEA registration before June 22. Make a documented, counsel-reviewed decision for every medical license. This is the hard deadline; the rest is recoverable, this is not.
- Reconfigure cost allocation in your seed-to-sale and accounting systems now. Tie every shared expense to a medical versus adult-use allocation key anchored in tag data, so your Schedule III deductions trace to source records.
- Preserve documentation for protective refund claims on open medical tax years, in case Treasury guidance opens retroactive relief, without booking that relief as income.
- Model both June 29 outcomes. Run capital plans against broad rescheduling by year-end and against an indefinite medical-only carve-out; the cash-flow gap should drive near-term decisions.
- Audit your TCPA consent and revocation stack before scaling any post-rescheduling marketing push. One-to-one consent is not optional and the per-message exposure is severe.
